 |
- The case was originally filed by Harbour Antibodies in 2021, alleging that Amgen and its subsidiary Teneobio infringed patents related to Harbour BioMed’s breakthrough antibody discovery platform
- A Delaware jury found the defendants guilty of willful infringement and upheld the validity of the patents in question, awarding Harbour BioMed the full $20.2 million in damages. The willful infringement finding allows the company to request the judge to triple the damages, potentially up to $60.6 million
- Harbour BioMed will continue to enforce its broader patent portfolio, focusing on another patent with significant financial implications, potentially valued at up to ten times the damages awarded in this case
- The ruling marks a comprehensive victory for Harbour BioMed, validating the strength of its proprietary transgenic mouse technology and its commitment to protecting scientific innovation
Shanghai, China; Cambridge, Massachusetts, USA; and Rotterdam, NetherlandsJune 15, 2026 /PRNewswire/ — Harbour BioMed (Stock Code: 02142.HK), a global biopharmaceutical company focused on the discovery and development of innovative antibody therapies for immune diseases, oncology, and other areas, today announced that a jury in the U.S. District Court for the District of Delaware has rendered a decisive verdict in favor of Harbour BioMed in its patent infringement lawsuit against Amgen Inc. and its subsidiary Teneobio, Inc. (collectively, “Amgen”). The ruling marks a comprehensive victory for Harbour BioMed, validating the strength of its proprietary transgenic mouse technology and its commitment to protecting scientific innovation.
The case was originally filed by Harbour Antibodies (a member of the Harbour BioMed group) in 2021, alleging that Amgen infringed multiple patents related to Harbour BioMed’s breakthrough antibody discovery platform, invented by Professor Frank Grosveld, one of Harbour BioMed’s founders (the “Grosveld patents”). As one of the most influential intellectual property disputes in the global antibody technology field, the case has attracted significant industry attention since its filing. After years of litigation, the case entered jury trial on June 8, 2026.
Prior to trial, in response to a court ruling, the company quickly adjusted its litigation strategy, adopting a focused two-step approach: actively advancing one patent case during the trial while simultaneously preparing to appeal a district court ruling on another patent to the U.S. Court of Appeals for the Federal Circuit. This strategy allowed the company to pursue patent protection for its technology while preserving the opportunity to enforce broader rights.
During the trial, Harbour BioMed presented compelling evidence. After hearing the evidence and closing arguments, the jury deliberated for only three hours before reaching a unanimous verdict in favor of Harbour BioMed on all claims:
- Amgen infringed the Grosveld patents;
- The infringement was willful;
- The Grosveld patents are valid;
- Harbour BioMed is entitled to $20,203,704 in damages—the full amount requested by the company.
Additionally, the jury’s finding of willful infringement allows the company to request the judge to triple the damages, potentially up to $60.6 million. This ruling is particularly notable in the District of Delaware, where high jury awards in complex patent cases are uncommon.
Dr. Wang Jinsong, Founder, Chairman, and CEO of Harbour BioMed, stated: “This is an epic victory for Harbour BioMed, reaffirming that Harbour BioMed is the true innovator behind this transformative technology. The jury’s finding of willful infringement sends a clear message: regardless of company size, scientific innovation must be respected. It also demonstrates our resilience, strategic focus, and unwavering commitment to ensuring that groundbreaking science is recognized, respected, and fairly compensated. This textbook patent battle victory also signals a new phase in the global antibody patent landscape.”
Going forward, Harbour BioMed will continue to enforce its broader patent portfolio, focusing on another patent with significant financial implications—potentially valued at up to ten times the damages awarded in this case. The company will also continue to actively protect its intellectual property across multiple fronts.
About Harbour BioMed
Harbour BioMed (Stock Code: 02142.HK) is a global biopharmaceutical company focused on the research and development of innovative drugs for immune diseases, oncology, and other areas. The company rapidly expands its innovative drug pipeline through proprietary research, joint development, and diversified international collaborations.
Harbour BioMed’s proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both heavy-chain-only (HCAb) and conventional dual-light-chain (H2L2) formats. The immune cell engagers (HBICE®) developed based on the HCAb antibody platform can achieve anti-tumor efficacy unattainable by traditional drug combination therapies. Additionally, the HCAb PLUS™ technology, developed on the HCAb antibody platform, provides comprehensive new molecular solutions for innovative multispecific drug development across different disease areas. Furthermore, leveraging the Harbour Mice® platform, Harbour BioMed has launched its first fully human AI HCAb model—the fully human HCAb generation and screening model—driven by its Hu-mAtrIx™ artificial intelligence (AI) platform, accelerating the development of innovative therapies.
Harbour Mice®, HBICE®, HCAb PLUS™, the single B cell cloning screening platform, and AI technology together form Harbour’s next-generation innovative therapeutic antibody research and development engine. For more information, please visit: www.harbourbiomed.com.